[ACE inhibitors and the kidney]

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Context:

• Elderly patients with diabetes, coronary heart disease, or peripheral vascular occlusion face increased risk of kidney function decline.
• Renal artery stenosis is common in these high-risk populations, complicating ACE inhibitor therapy.
• Proteinuria and hypertension are key indicators for ACE inhibitor use in kidney protection.

Purpose:

• To outline the kidney-protective mechanisms of ACE inhibitors.
• To highlight risks associated with ACE inhibitor use in specific patient groups, including the elderly and those with renal insufficiency.
• To provide recommendations for safe and effective ACE inhibitor initiation and management.

Summary:

• ACE inhibitors offer renal protection through multiple pathways: reducing systemic and intraglomerular pressure, exhibiting antiproliferative effects, and lowering proteinuria.
• Special considerations are necessary for elderly patients, particularly those with diabetes, coronary heart disease, or peripheral vascular disease, due to the prevalence of renal artery stenosis.
• Dose adjustments and cautious initiation (starting low, going slow) are recommended for patients with renal insufficiency, those at risk for renal artery stenosis, and those on diuretics to mitigate hyperkalemia risk.
• Fosinopril is noted as an exception requiring less dose reduction in renal insufficiency.
• Once-daily dosing is advised for improved patient compliance.

Impact:

• Optimized ACE inhibitor therapy can preserve kidney function and reduce cardiovascular events in at-risk populations.
• Understanding the risks of hyperkalemia and renal artery stenosis allows for proactive patient management.
• Implementing 'start low, go slow' and once-daily dosing strategies enhances patient safety and adherence, improving long-term outcomes.